Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational agent for this penile cancer study.
Epistemonikos ID: a6302dcb4d197db63682ee75252723577733fa06
First added on: May 17, 2024